MS-3095

A 65-year-old woman has been referred to the osteoporosis clinic by her GP for alternate bone-sparing treatment. She recently had a bone density scan after experiencing a low impact distal radial fracture. Her T-score for her hip and spine were -2.6 and -2.2 respectively. Despite trying different bisphosphate preparations such as alendronate and risedronate, she experienced significant gastrointestinal side effects. The clinic has decided to start her on a RANKL inhibitor. What treatment is being referred to?